Loading
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Regular session
$11.24
−$0.45 · -3.85%
Regular session · ET · Market data may be delayed.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Day range
Current $11.24
52-week range
Current $11.24
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
38
Expensive
Sentiment
67
Bullish
Risk
57
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Day range
Current $11.24
52-week range
Current $11.24
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 118.44M USD | 119.04M USD | 87.52M USD | 65.05M USD | 44.03M USD |
| Selling, general, and administrative | 60.6M USD | 59.17M USD | 49.4M USD | 45.35M USD | 39.19M USD |
| Operating expenses | 179.04M USD | 178.21M USD | 136.92M USD | 110.4M USD | 83.22M USD |
| Interest income | 7.18M USD | 8.27M USD | 4.62M USD | — | — |
| Interest expense | 4.52M USD | 4.48M USD | 2.2M USD | — | — |
| Depreciation and amortization | 216K USD | 233K USD | 242K USD | 330K USD | 175K USD |
| Operating income | −179.04M USD | −178.21M USD | −136.92M USD | −110.4M USD | −83.22M USD |
| Net income | −287.86M USD | −155.12M USD | −118.46M USD | −91.51M USD | −71.74M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.63
65.75% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG54.58M2.59%1.56B USD0.75%$48.685-2.90%
iShares Biotechnology ETFIBB10.05M0.10%10.4B USD0.44%$197.91-2.67%
AdvisorShares Psychedelics ETFPSIL5.51M11.42%48.22M USD1.84%$20.72-2.08%
ALPS Medical Breakthroughs ETFSBIO2.06M1.09%188.26M USD0.50%$53.025-2.04%
State Street SPDR S&P International Small Cap ETFGWX1.13M0.12%925.91M USD0.40%$45.035-0.98%
Simplify Propel Opportunities ETFSURI1.06M1.41%74.84M USD2.82%$16.945+0.56%
ROBO Global Healthcare Technology and Innovation ETFHTEC895.91K0.95%103.46M USD0.80%$41.70-2.04%
AdvisorShares Dorsey WrightAADR685.15K1.84%37.27M USD1.17%$80.66-0.43%ARK Genomic Revolution ETFARKGiShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P International Small Cap ETFGWXSimplify Propel Opportunities ETFSURIROBO Global Healthcare Technology and Innovation ETFHTECAdvisorShares Dorsey WrightAADRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
